AstraZeneca has appointed Sean Bohen, M.D., Ph.D., as executive vice president of global medicines development and chief medical officer. He will join the company on Sept. 15.

Bohen will be responsible for driving the progress of AstraZeneca’s portfolio of small molecules and biologics investigational medicines through late-stage development to regulatory approval. As chief medical officer, he will be responsible for patient safety across the entire AstraZeneca and MedImmune portfolio.

Bohen joins AstraZeneca from Genentech where he most recently was senior vice president of early development. He oversaw preclinical and clinical development programs across all therapy areas, including oncology, respiratory and autoimmune diseases, to deliver trial-ready drug candidates to late-stage development. Before then, he held a number of positions in early and late-stage development, playing a crucial role in the growth and progress of the Genentech/Roche portfolio.

Previously, Bohen was a clinical instructor in oncology at Stanford University School of Medicine, a research associate at the Howard Hughes Medical Institute and a postdoctoral fellow at the National Cancer Institute.